Literature DB >> 25751063

A versatile modular vector system for rapid combinatorial mammalian genetics.

Joachim Albers, Claudia Danzer, Markus Rechsteiner, Holger Lehmann, Laura P Brandt, Tomas Hejhal, Antonella Catalano, Philipp Busenhart, Ana Filipa Gonçalves, Simone Brandt, Peter K Bode, Beata Bode-Lesniewska, Peter J Wild, Ian J Frew.   

Abstract

Here, we describe the multiple lentiviral expression (MuLE) system that allows multiple genetic alterations to be introduced simultaneously into mammalian cells. We created a toolbox of MuLE vectors that constitute a flexible, modular system for the rapid engineering of complex polycistronic lentiviruses, allowing combinatorial gene overexpression, gene knockdown, Cre-mediated gene deletion, or CRISPR/Cas9-mediated (where CRISPR indicates clustered regularly interspaced short palindromic repeats) gene mutation, together with expression of fluorescent or enzymatic reporters for cellular assays and animal imaging. Examples of tumor engineering were used to illustrate the speed and versatility of performing combinatorial genetics using the MuLE system. By transducing cultured primary mouse cells with single MuLE lentiviruses, we engineered tumors containing up to 5 different genetic alterations, identified genetic dependencies of molecularly defined tumors, conducted genetic interaction screens, and induced the simultaneous CRISPR/Cas9-mediated knockout of 3 tumor-suppressor genes. Intramuscular injection of MuLE viruses expressing oncogenic H-RasG12V together with combinations of knockdowns of the tumor suppressors cyclin-dependent kinase inhibitor 2A (Cdkn2a), transformation-related protein 53 (Trp53), and phosphatase and tensin homolog (Pten) allowed the generation of 3 murine sarcoma models, demonstrating that genetically defined autochthonous tumors can be rapidly generated and quantitatively monitored via direct injection of polycistronic MuLE lentiviruses into mouse tissues. Together, our results demonstrate that the MuLE system provides genetic power for the systematic investigation of the molecular mechanisms that underlie human diseases.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25751063      PMCID: PMC4396471          DOI: 10.1172/JCI79743

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  60 in total

1.  iRFP is a sensitive marker for cell number and tumor growth in high-throughput systems.

Authors:  Andreas K Hock; Pearl Lee; Oliver Dk Maddocks; Susan M Mason; Karen Blyth; Karen H Vousden
Journal:  Cell Cycle       Date:  2013-10-31       Impact factor: 4.534

2.  Deep-tissue photoacoustic tomography of a genetically encoded near-infrared fluorescent probe.

Authors:  Grigory S Filonov; Arie Krumholz; Jun Xia; Junjie Yao; Lihong V Wang; Vladislav V Verkhusha
Journal:  Angew Chem Int Ed Engl       Date:  2011-12-23       Impact factor: 15.336

3.  Cooperation of oncogenic K-ras and p53 deficiency in pleomorphic rhabdomyosarcoma development in adult mice.

Authors:  H Tsumura; T Yoshida; H Saito; K Imanaka-Yoshida; N Suzuki
Journal:  Oncogene       Date:  2006-06-19       Impact factor: 9.867

4.  Negative regulation of neural stem/progenitor cell proliferation by the Pten tumor suppressor gene in vivo.

Authors:  M Groszer; R Erickson; D D Scripture-Adams; R Lesche; A Trumpp; J A Zack; H I Kornblum; X Liu; H Wu
Journal:  Science       Date:  2001-11-01       Impact factor: 47.728

5.  Sarcomas induced in discrete subsets of prospectively isolated skeletal muscle cells.

Authors:  Simone Hettmer; Jianing Liu; Christine M Miller; Melissa C Lindsay; Cynthia A Sparks; David A Guertin; Roderick T Bronson; David M Langenau; Amy J Wagers
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-30       Impact factor: 11.205

6.  Lentiviral vector design for multiple shRNA expression and durable HIV-1 inhibition.

Authors:  Olivier ter Brake; Karen 't Hooft; Ying Poi Liu; Mireille Centlivre; Karin Jasmijn von Eije; Ben Berkhout
Journal:  Mol Ther       Date:  2008-01-15       Impact factor: 11.454

7.  Life in the fast lane: mammalian disease models in the genomics era.

Authors:  Lukas E Dow; Scott W Lowe
Journal:  Cell       Date:  2012-03-16       Impact factor: 41.582

8.  Targeting oxidative stress in embryonal rhabdomyosarcoma.

Authors:  Xiang Chen; Elizabeth Stewart; Anang A Shelat; Chunxu Qu; Armita Bahrami; Mark Hatley; Gang Wu; Cori Bradley; Justina McEvoy; Alberto Pappo; Sheri Spunt; Marcus B Valentine; Virginia Valentine; Fred Krafcik; Walter H Lang; Monika Wierdl; Lyudmila Tsurkan; Viktor Tolleman; Sara M Federico; Chris Morton; Charles Lu; Li Ding; John Easton; Michael Rusch; Panduka Nagahawatte; Jianmin Wang; Matthew Parker; Lei Wei; Erin Hedlund; David Finkelstein; Michael Edmonson; Sheila Shurtleff; Kristy Boggs; Heather Mulder; Donald Yergeau; Steve Skapek; Douglas S Hawkins; Nilsa Ramirez; Philip M Potter; John A Sandoval; Andrew M Davidoff; Elaine R Mardis; Richard K Wilson; Jinghui Zhang; James R Downing; Michael A Dyer
Journal:  Cancer Cell       Date:  2013-12-09       Impact factor: 31.743

9.  Combined mutation of Vhl and Trp53 causes renal cysts and tumours in mice.

Authors:  Joachim Albers; Michal Rajski; Désirée Schönenberger; Sabine Harlander; Peter Schraml; Adriana von Teichman; Strahil Georgiev; Peter J Wild; Holger Moch; Wilhelm Krek; Ian J Frew
Journal:  EMBO Mol Med       Date:  2013-04-22       Impact factor: 12.137

10.  Repurposing CRISPR/Cas9 for in situ functional assays.

Authors:  Abba Malina; John R Mills; Regina Cencic; Yifei Yan; James Fraser; Laura M Schippers; Marilène Paquet; Josée Dostie; Jerry Pelletier
Journal:  Genes Dev       Date:  2013-12-01       Impact factor: 11.361

View more
  29 in total

1.  Hypoxia-Inducible PIM Kinase Expression Promotes Resistance to Antiangiogenic Agents.

Authors:  Andrea L Casillas; Rachel K Toth; Alva G Sainz; Neha Singh; Ankit A Desai; Andrew S Kraft; Noel A Warfel
Journal:  Clin Cancer Res       Date:  2017-10-30       Impact factor: 12.531

2.  A splice junction-targeted CRISPR approach (spJCRISPR) reveals human FOXO3B to be a protein-coding gene.

Authors:  Evan E Santo; Jihye Paik
Journal:  Gene       Date:  2018-06-18       Impact factor: 3.688

3.  Proteomic identification of a marker signature for MAPKi resistance in melanoma.

Authors:  Verena Paulitschke; Ossia Eichhoff; Christopher Gerner; Philipp Paulitschke; Andrea Bileck; Thomas Mohr; Phil F Cheng; Alexander Leitner; Emmanuella Guenova; Ieva Saulite; Sandra N Freiberger; Anja Irmisch; Bernhard Knapp; Nina Zila; Theodora-Pagona Chatziisaak; Jürgen Stephan; Joanna Mangana; Rainer Kunstfeld; Hubert Pehamberger; Ruedi Aebersold; Reinhard Dummer; Mitchell P Levesque
Journal:  EMBO J       Date:  2019-06-26       Impact factor: 11.598

Review 4.  Is toxicant-induced Sertoli cell injury in vitro a useful model to study molecular mechanisms in spermatogenesis?

Authors:  Nan Li; Dolores D Mruk; Will M Lee; Chris K C Wong; C Yan Cheng
Journal:  Semin Cell Dev Biol       Date:  2016-01-15       Impact factor: 7.727

Review 5.  Development and potential applications of CRISPR-Cas9 genome editing technology in sarcoma.

Authors:  Tang Liu; Jacson K Shen; Zhihong Li; Edwin Choy; Francis J Hornicek; Zhenfeng Duan
Journal:  Cancer Lett       Date:  2016-01-21       Impact factor: 8.679

Review 6.  Sites of retroviral DNA integration: From basic research to clinical applications.

Authors:  Erik Serrao; Alan N Engelman
Journal:  Crit Rev Biochem Mol Biol       Date:  2015-10-28       Impact factor: 8.250

7.  BMPR2 acts as a gatekeeper to protect endothelial cells from increased TGFβ responses and altered cell mechanics.

Authors:  Christian Hiepen; Jerome Jatzlau; Susanne Hildebrandt; Branka Kampfrath; Melis Goktas; Arunima Murgai; Jose Luis Cuellar Camacho; Rainer Haag; Clemens Ruppert; Gerhard Sengle; Elisabetta Ada Cavalcanti-Adam; Kerstin G Blank; Petra Knaus
Journal:  PLoS Biol       Date:  2019-12-11       Impact factor: 8.029

Review 8.  Translatable gene therapy for lung cancer using Crispr CAS9-an exploratory review.

Authors:  Jishnu Nair; Abhishek Nair; Soundaram Veerappan; Dwaipayan Sen
Journal:  Cancer Gene Ther       Date:  2019-06-20       Impact factor: 5.987

9.  Tumour modelling using viral vectors.

Authors:  Ian J Frew
Journal:  Oncotarget       Date:  2015-06-10

10.  Increased Efficiency for Biallelic Mutations of the CCR5 Gene by CRISPR-Cas9 Using Multiple Guide RNAs As a Novel Therapeutic Option for Human Immunodeficiency Virus.

Authors:  Dong Lin; Stefan H Scheller; Madeline M Robinson; Reza Izadpanah; Eckhard U Alt; Stephen E Braun
Journal:  CRISPR J       Date:  2021-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.